Objective To investigate the efficacy and adverse effects of KLT combined with chemotherapy for colorectal liver metastases. Methods 78 cases of advanced colorectal patients with inoperable liver metastases were randomly divided into chemotherapy group and combination group with each of 39 cases.Chemotherapy group were treated with the FOLFOX4 chemotherapy regimen,and the combination group were treated with KLT injection on the basis of this. The clinical efficacy and adverse effects were observed after four cycles of treatment. Results Of the combination group and the chemotherapy group,the overall response rates were 35.9% and 30.8% respectively (P >0.05),the overall response rates of CEA were 71.8% and 64.1%(P >0.05),and the total effective rates of Karnofsky score were 69.2% and 46.2%(P <0.05),the overall response rates of pain were 66.7% and 33.3%(P <0.05). The incidences of gastrointestinal reactions,abnormal liver function and fatigue of the combined group were significantly reduced(P <0.05). Conclusion KLT combined with chemotherapy can improve the clinical symptoms,reduce the adverse effects of chemotherapy in the treatment of advanced colorectal cancer.% 目的探讨康莱特注射液联合化疗治疗结直肠癌肝转移的疗效与不良反应.方法入选晚期结直肠癌肝转移无法手术的患者78例，随机分为化疗组与联合组各39例.化疗组采用 FOLFOX4化疗方案，联合组在此基础上加用康莱特注射液，治疗4个周期后观察临床疗效与不良反应情况.结果联合治疗组与单用化疗组总缓解率分别为35.9%和30.8%(P >0.05)；CEA 总缓解率分别为71.8%和64.1%(P >0.05)；Karnofsky 评分总有效率分别为69.2%和46.2%(P <0.05)；疼痛总缓解率分别为66.7%和33.3%(P <0.01).联合组消化道反应、肝功能异常、乏力的发生率显著降低(P <0.05).结论康莱特联合化疗治疗晚期结直肠癌，可改善患者的临床症状，降低化疗不良反应.
展开▼
